Received Feb 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
Shingles happened in the 3 year span; Drug dose administration interval too long; This non-serious case was reported by a consumer via call center representative and described the occurrence of shingles in a male patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 2nd dose of Shingrix and the 1st dose of Shingrix. On an unknown date, not applicable after receiving Shingrix and an unknown time after receiving Shingrix, the patient experienced shingles (Verbatim: Shingles happened in the 3 year span) and drug dose administration interval too long (Verbatim: Drug dose administration interval too long). The outcome of the shingles and drug dose administration interval too long were unknown. It was unknown if the reporter considered the shingles to be related to Shingrix. It was unknown if the company considered the shingles to be related to Shingrix. Additional Information: GSK Receipt Date: 09-JAN-2025 Consumer was the reporter. The patient stated that he had his first dose of Shingrix about 3 years ago. The patient recently had his second dose of Shingrix administered late dose. The patient stated that he believed he has a few cases of shingles in those three years lack of effect. All cases of shingles happened in the 3 year span prior to having his second dose of Shingrix administered. The patient received 2nd dose of Shingrix later than the recommended schedule, which led to lengthening of vaccination schedule.